| Literature DB >> 24337214 |
Sedat Ozcan1, Ali Kemal Gür, Ali Umit Yener, Dolunay Odabaşi.
Abstract
OBJECTIVE: This study aimed to compare the results of one-and two-stage basilic vein transposition (BVT) in haemodialysis patients.Entities:
Mesh:
Year: 2013 PMID: 24337214 PMCID: PMC3896105 DOI: 10.5830/CVJA-2013-077
Source DB: PubMed Journal: Cardiovasc J Afr ISSN: 1015-9657 Impact factor: 1.167
Demographics Of The Patients
| p | |||
| Gender (M/F) | M = 28 (59%) | M = 36 (61%) | NS |
| F = 19 (41%) | F = 23 (39%) | NS | |
| Mean age (years) | M = 43.1 (± 16) | M = 44.9 (± 14) | NS |
| F = 42.5 (± 13) | F = 44.1 (± 13) | NS | |
| ESRF duration (months) | M = 63.1 (± 17) | M = 61.7 (± 20) | NS |
| F = 64.5 (± 18) | F = 63.3 (± 21) | NS | |
| Previously opened AVF | M = 5 (± 1.6) | M = 5.2 (± 1.7) | NS |
| F = 5.45 (± 1.7) | F =5.0 (± 1.6) | NS | |
| Hypertension | 15 | 14 | NS |
| Diabetes mellitus | 9 | 11 | NS |
| Heart disease | 4 | 3 | NS |
| Peripheral vascular disease | 2 | 3 | NS |
| Smoking | 9 | 11 | NS |
| Mean LDL-C (mmol/l) | 157 ± 26 | 145 ± 21 | NS |
| Mean basilic vein diameter (mm) | 3.46 ± 0.2 | 2.79 ± 0.1 | < 0.05 |
| Mean brachial artery diameter (mm) | 3.71 ± 1.4 | 3.63 ± 1.5 | NS |
BVT: basilic vein transposition, AVF: arteio-venous fistula, NS: non-significant, LDL-C: low-density lipoprotein cholesterol, ESRF: end-stage renal failure, M = male, F = female.
Bleeding–Clotting Times Of The Groups
| PT (sec) | 17 ± 4 | 16 ± 4 | NS |
| APTT (sec) | 38 ± 7 | 41 ± 7 | NS |
| INR | 1.3 ± 0.5 | 1.5 ± 0.7 | NS |
| Platelet count (103/ml) | 385 ± 70 | 367 ± 67 | NS |
| Bleeding time (min) | 6.1 ± 1.3 | 5.7 ± 1.2 | NS |
| Clotting time (min) | 7.1 ± 2.3 | 7.3 ± 2.1 | NS |
| Protein C (%) | 89 ± 28 | 92 ± 31 | NS |
| D-dimer (ng/dl) | 275 ± 73 | 321 ± 67 | NS |
| Fibrinogen (g/l) | 3.2 ± 0.7 | 2.8 ± 0.5 | NS |
PT: prothrombin time, APTT: active partial thromboplastin time, INR: international normalised ratio.
Complications
| p | |||
| Mortality | 3 (6%) | 2 (4%) | NS |
| Maturation rate | 31 (66%) | 45 (77%) | < 0.05 |
| Infection | 6 (12%) | 5 (10%) | NS |
| Thrombosis | 16 (34%) | 11 (23%) | < 0.05 |
| Bleeding | 17 (36%) | 7 (14%) | < 0.05 |
| Haematoma | 8 (17%) | 3 (6%) | < 0.05 |
| Pseudo-aneurysm | 2 (4%) | 3 (6%) | NS |
| Steal syndrome | 4 (8%) | 3 (6%) | NS |
| Oedema | 5 (10%) | 6 (10%) | NS |
| Mean fistula maturation time (day) | 41 ± 14 | 64 ± 28 | < 0.05 |
| Mean fistula flow rate (ml/min) | 280 ± 23 | 300 ± 31 | NS |
NS: non-significant.
Assisted Interventional Surgery Rates
| p | |||
| Early (≤ 10 day) thrombosis | 10 (21%) | 6 (12%) | < 0.05 |
| Bleeding | 8 (17%) | 3 (6%) | < 0.05 |
| Haematoma | 5 (10%) | 1 (2%) | < 0.05 |
| Late (≥ 10 day) thrombosis | 9 (20%) | 11 (22%) | NS |
| Pseudo-aneurysm | 2 (4%) | 3 (6%) | NS |
| Steal syndrome | 2 (4%) | 3 (6%) | NS |
NS: non-significant.
Secondary Patency Rates Of Group 1
| 6 | 40 | 4 | 0.15 | 0.85 | 85.00 |
| 12 | 36 | 4 | 0.10 | 0.90 | 76.00 |
| 18 | 35 | 1 | 0.02 | 0.98 | 74.00 |
| 24 | 34 | 1 | 0.02 | 0.98 | 72.00 |
| 30 | 33 | 1 | 0.02 | 0.98 | 70.00 |
| 36 | 31 | 2 | 0.06 | 0.94 | 66.00 |
Primary Patency Rates Of Group 1
| 6 | 39 | 8 | 0.17 | 0.83 | 83.00 |
| 12 | 33 | 6 | 0.15 | 0.85 | 70.00 |
| 18 | 32 | 1 | 0.03 | 0.97 | 68.00 |
| 24 | 30 | 2 | 0.06 | 0.94 | 64.00 |
| 30 | 28 | 2 | 0.07 | 0.93 | 60.00 |
| 36 | 27 | 1 | 0.03 | 0.97 | 57.00 |
Secondary Patency Rates Of Group 2
| 6 | 46 | 3 | 0.06 | 0.94 | 94.00 |
| 12 | 44 | 2 | 0.04 | 0.96 | 90.00 |
| 18 | 41 | 3 | 0.07 | 0.93 | 84.00 |
| 24 | 40 | 1 | 0.02 | 0.98 | 82.00 |
| 30 | 39 | 1 | 0.02 | 0.98 | 80.00 |
| 36 | 38 | 1 | 0.02 | 0.98 | 77.00 |
Primary Patency Rates Of Group 2
| 6 | 43 | 6 | 0.12 | 0.88 | 88.00 |
| 12 | 41 | 2 | 0.04 | 0.96 | 84.00 |
| 18 | 39 | 2 | 0.05 | 0.95 | 80.00 |
| 24 | 36 | 3 | 0.07 | 0.93 | 73.00 |
| 30 | 35 | 1 | 0.03 | 0.97 | 71.00 |
| 36 | 34 | 1 | 0.02 | 0.98 | 69.00 |
Fig. 1.Secondary patency rates of the two groups.
Fig. 2.Primary patency rates of the two groups.